Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-20T07:38:12.577Z Has data issue: false hasContentIssue false

Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine

Published online by Cambridge University Press:  25 April 2002

C. K. NGICHABE
Affiliation:
Kenya Agricultural Research Institute, National Veterinary Research Centre Muguga, P.O. Box 32 Kikuyu, Kenya
H. M. WAMWAYI
Affiliation:
Kenya Agricultural Research Institute, National Veterinary Research Centre Muguga, P.O. Box 32 Kikuyu, Kenya
E. K. NDUNGU
Affiliation:
Kenya Agricultural Research Institute, National Veterinary Research Centre Muguga, P.O. Box 32 Kikuyu, Kenya
P. K. MIRANGI
Affiliation:
Kenya Agricultural Research Institute, National Veterinary Research Centre Muguga, P.O. Box 32 Kikuyu, Kenya
C. J. BOSTOCK
Affiliation:
Department of Molecular Biology, Institute for Animal Health, Pirbright Laboratory, Pirbright, Woking, Surrey, GU24 0NF, UK
D. N. BLACK
Affiliation:
Department of Molecular Biology, Institute for Animal Health, Pirbright Laboratory, Pirbright, Woking, Surrey, GU24 0NF, UK Present address: Wright Fleming Institute, Department of Infectious Diseases, Imperial College Medical School, Norfolk Place, London W21PG, UK.
T. BARRETT
Affiliation:
Department of Molecular Biology, Institute for Animal Health, Pirbright Laboratory, Pirbright, Woking, Surrey, GU24 0NF, UK
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Cattle were vaccinated with a recombinant capripox-rinderpest vaccine designed to protect cattle from infection with either rinderpest virus (RPV) or lumpy skin disease virus (LSDV). Vaccination did not induce any adverse clinical responses or show evidence of transmission of the vaccine virus to in-contact control animals. Approximately 50% of the cattle were solidly protected from challenge with a lethal dose of virulent RPV 2 years after vaccination while at 3 years approx. 30% were fully protected. In the case of LSDV, all of 4 vaccinated cattle challenged with virulent LSDV at 2 years were completely protected from clinical disease while 2 of 5 vaccinated cattle were completely protected at 3 years. The recombinant vaccine showed no loss of potency when stored lyophylized at 4 °C for up to 1 year. These results indicate that capripoxvirus is a suitable vector for the development of safe, effective and stable recombinant vaccines for cattle.

Type
Short Paper
Copyright
© 2002 Cambridge University Press